{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T22:47:38Z","timestamp":1769208458633,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.msard.2022.104030","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T12:11:45Z","timestamp":1657023105000},"page":"104030","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-9059","authenticated-orcid":false,"given":"Richard","family":"Leckey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liborio","family":"Borsellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea M","family":"Rawlings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ashkenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Suri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2022.104030_bib0009","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/19420862.2018.1474996","article-title":"FcgammaRIIIa-dependent IFN-gamma release in whole blood assay is predictive of therapeutic IgG1 antibodies safety","volume":"10","author":"Alakhras","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.msard.2022.104030_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101412","article-title":"Clinical observation during alemtuzumab administration","volume":"37","author":"Allen","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2022.104030_bib0016","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(19)30076-6","article-title":"Intracerebral haemorrhage during alemtuzumab administration","volume":"18","author":"Azevedo","year":"2019","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.msard.2022.104030_bib0028","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1111\/ene.15054","article-title":"Alemtuzumab in multiple sclerosis: a retrospective analysis of occult hemorrhagic magnetic resonance imaging lesions and risk factors","volume":"28","author":"Bachmann","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2022.104030_bib0012","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.msard.2017.09.028","article-title":"Marked neutropenia: significant but rare in people with multiple sclerosis after alemtuzumab treatment","volume":"18","author":"Baker","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2022.104030_bib0029","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7224\/1537-2073.2014-030","article-title":"Prevention and management of infusion-associated reactions in the comparison of alemtuzumab and rebif(R) efficacy in multiple sclerosis (CARE-MS) program","volume":"17","author":"Caon","year":"2015","journal-title":"Int. J. MS Care"},{"issue":"2","key":"10.1016\/j.msard.2022.104030_bib0021","doi-asserted-by":"crossref","first-page":"53","DOI":"10.7224\/1537-2073.2018-076","article-title":"Effect of alemtuzumab infusions on vital signs: a prospective observational study in patients with relapsing-remitting multiple sclerosis","volume":"22","author":"Chinea","year":"2020","journal-title":"Int. J. MS Care"},{"issue":"9856","key":"10.1016\/j.msard.2022.104030_bib0002","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet North Am. Ed."},{"key":"10.1016\/j.msard.2022.104030_bib0008","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#","article-title":"Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis","volume":"46","author":"Coles","year":"1999","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2022.104030_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420982134","article-title":"Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial","volume":"14","author":"Coles","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2022.104030_bib0003","series-title":"Proceedings of the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis","article-title":"Alemtuzumab maintains efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 10 years in RRMS patients: CARE-MS I follow-up (TOPAZ Study)","author":"Coles","year":"2021"},{"issue":"3","key":"10.1016\/j.msard.2022.104030_bib0013","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1586\/ern.12.5","article-title":"Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis","volume":"12","author":"Costelloe","year":"2012","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.msard.2022.104030_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103810","article-title":"Alemtuzumab induced hemodynamic change in relapsing multiple sclerosis occurs independent of corticosteroid premedication - a retrospective multicentre study","volume":"63","author":"Di Pauli","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104030_bib0017","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/1352458519828663","article-title":"Spontaneous multiple cervical artery dissections after alemtuzumab","volume":"26","author":"Durand-Dubief","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2022.104030_bib0033","unstructured":"European Medicines Agency. Summary of risk management plan for LEMTRADA (Alemtuzumab). https:\/\/www.ema.europa.eu\/en\/documents\/rmp-summary\/lemtrada-epar-risk-management-plan-summary_en.pdf, accessed December 2021."},{"key":"10.1016\/j.msard.2022.104030_bib0014","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.msard.2018.12.004","article-title":"Autoimmune encephalitis following alemtuzumab treatment of multiple sclerosis","volume":"28","author":"Giarola","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104030_bib0005","series-title":"Proceedings of the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis","article-title":"Early treatment with alemtuzumab maintains its efficacy on clinical and MRI disease activity outcomes, including slowing of brain volume loss, over 10 years in RRMS patients: CARE-MS II follow-up (TOPAZ Study)","author":"Giovannoni","year":"2021"},{"issue":"6","key":"10.1016\/j.msard.2022.104030_bib0015","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1177\/1352458520913277","article-title":"Alemtuzumab: Rare serious adverse events of a high-efficacy drug","volume":"26","author":"Hartung","year":"2020","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2022.104030_bib0018","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1186\/s13104-019-4507-6","article-title":"Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis","volume":"12","author":"Holmoy","year":"2019","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.msard.2022.104030_bib0025","unstructured":"Genzyme Corporation. Lemtrada (alemtuzumab). Highlights of prescribing information, May 2022. https:\/\/products.sanofi.us\/lemtrada\/lemtrada.html#Top, accessed July 2022."},{"key":"10.1016\/j.msard.2022.104030_bib0031","unstructured":"https:\/\/www.ema.europa.eu\/en\/documents\/referral\/lemtrada-article-20-procedure-scientific-conclusions_en.pdf, accessed December 2021."},{"key":"10.1016\/j.msard.2022.104030_bib0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1352458520904277","article-title":"Elevated D-dimer as an immediate response to alemtuzumab treatment","volume":"27","author":"Libertinova","year":"2021","journal-title":"Mult. Scler. J."},{"issue":"2","key":"10.1016\/j.msard.2022.104030_bib0011","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/NAN.0000000000000127","article-title":"Best practices in alemtuzumab administration: practical recommendations for infusion in patients with multiple sclerosis","volume":"39","author":"McEwan","year":"2016","journal-title":"J. Infus. Nurs."},{"issue":"Suppl. 2","key":"10.1016\/j.msard.2022.104030_bib0024","first-page":"643","article-title":"Blood pressure excursions with alemtuzumab in Canadian patients with relapsing remitting multiple sclerosis","volume":"27","author":"Morrow","year":"2021","journal-title":"Mult Scler J"},{"key":"10.1016\/j.msard.2022.104030_bib0001","unstructured":"Sanofi-Genzyme. Lemtrada (alemtuzumab). Product monograph, February 2021. https:\/\/pdf.hres.ca\/dpd_pm\/00060032.PDF, accessed December 2021."},{"key":"10.1016\/j.msard.2022.104030_bib0026","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.msard.2017.07.019","article-title":"Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis","volume":"17","author":"Sega-Jazbec","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2022.104030_bib0023","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/ene.14633","article-title":"Blood pressure changes during alemtuzumab infusion for multiple sclerosis patients","volume":"28","author":"Shosha","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.104030_bib0006","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1007\/s00415-020-09983-1","article-title":"Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223","volume":"267","author":"Steingo","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.104030_bib0027","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.msard.2017.08.001","article-title":"Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis","volume":"17","author":"Thomas","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2022.104030_bib0010","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1212\/NXI.0000000000000228","article-title":"Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS","volume":"3","author":"Thomas","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"Suppl. 1","key":"10.1016\/j.msard.2022.104030_bib0019","first-page":"477","article-title":"Safety of alemtuzumab in RRMS patients during the peri-infusion period: clinical trial and postmarketing experience","volume":"27","author":"Vermersch","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2022.104030_bib0022","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.msard.2019.01.019","article-title":"Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD)","volume":"29","author":"Vukusic","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104030_bib0007","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1172\/JCI119110","article-title":"Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcGammaRIII) and CD11a\/CD18 (LFA-1) on NK cells","volume":"98","author":"Wing","year":"1996","journal-title":"J. Clin. Invest."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:48Z","timestamp":1761901488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822005387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":33,"alternative-id":["S2211034822005387"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104030","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104030"}}